{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:12:53Z","timestamp":1794355973983,"version":"4.9.0"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100012781","name":"Merck Sharp and Dohme K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Plasma Epstein\u2013Barr virus (EBV) DNA has clinical utility for prognosis, recurrence, surveillance, and treatment response in nasopharyngeal carcinoma (NPC). This exploratory analysis evaluated associations between plasma EBV DNA load and clinical outcomes in participants treated with pembrolizumab or chemotherapy in the phase 3 KEYNOTE\u2010122 trial (NCT02611960).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Participants with platinum\u2010pretreated, histologically confirmed, EBV\u2010positive, recurrent\/metastatic NPC were randomly assigned (1:1) to pembrolizumab 200\u2009mg intravenously every 3\u2009weeks (\u2264\u200935\u2009cycles) or standard of care (SOC; investigator's choice of capecitabine, gemcitabine, or docetaxel). Associations between baseline plasma EBV DNA load as a continuous variable and plasma EBV DNA fold change at cycle 2\u2009day 1 (C2D1), with clinical outcomes (progression\u2010free survival [PFS], overall survival [OS], and objective response rate [ORR]) were evaluated within each treatment arm. Nominal significance was prespecified at 0.05 for 1\u2010sided\n                      <jats:italic>p<\/jats:italic>\n                      values.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 228 treated participants, 215 (94.3%) had evaluable baseline plasma EBV DNA load data (pembrolizumab, 111; SOC, 104). Baseline plasma EBV DNA load was negatively associated with PFS and OS for pembrolizumab and SOC (both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.005) but not ORR (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.105, pembrolizumab;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.473, SOC). Larger decreases in plasma EBV DNA load at C2D1 relative to baseline were associated with improved PFS, OS, and ORR for pembrolizumab and SOC (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.005).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Higher baseline plasma EBV DNA load was negatively associated with outcomes in participants with NPC treated with pembrolizumab or SOC. These findings provide additional support for plasma EBV DNA as a prognostic biomarker for NPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      ,\n                      <jats:styled-content style=\"fixed-case\">NCT02611960<\/jats:styled-content>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71496","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T14:24:41Z","timestamp":1770128681000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Analysis of Plasma Epstein\u2013Barr Virus\n                    <scp>DNA<\/scp>\n                    and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent\/Metastatic Nasopharyngeal Cancer in\n                    <scp>KEYNOTE<\/scp>\n                    \u2010122"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-8091","authenticated-orcid":false,"given":"Anthony T. C.","family":"Chan","sequence":"first","affiliation":[{"name":"State Key Laboratory in Translational Oncology, School of Biomedical Sciences, Sir YK Pao Centre for Cancer The Chinese University of Hong Kong  Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6283-978X","authenticated-orcid":false,"given":"Victor Ho Fun","family":"Lee","sequence":"additional","affiliation":[{"name":"The University of Hong Kong  Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruey\u2010Long","family":"Hong","sequence":"additional","affiliation":[{"name":"National Taiwan University Cancer Center  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung\u2010Ju","family":"Ahn","sequence":"additional","affiliation":[{"name":"Samsung Medical Center, Sungkyunkwan University School of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan Qin","family":"Chong","sequence":"additional","affiliation":[{"name":"National University Cancer Institute  Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Spreafico","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung\u2010Bae","family":"Kim","sequence":"additional","affiliation":[{"name":"Asan Medical Center University of Ulsan College of Medicine  Seoul Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwo Fuang","family":"Ho","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Universiti Malaya  Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla B.","family":"Caguioa","sequence":"additional","affiliation":[{"name":"St. Luke's Medical Center University of Santo Tomas Faculty of Medicine and Surgery  Manila Philippines"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6535-6345","authenticated-orcid":false,"given":"Nuttapong","family":"Ngamphaiboon","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Ramathibodi Hospital Mahidol University  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona F.","family":"Swaby","sequence":"additional","affiliation":[{"name":"Merck &amp; Co. Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9688-5442","authenticated-orcid":false,"given":"Bo","family":"Wei","sequence":"additional","affiliation":[{"name":"Merck &amp; Co. Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Webber","sequence":"additional","affiliation":[{"name":"Merck &amp; Co. Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kang","sequence":"additional","affiliation":[{"name":"Merck &amp; Co. Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Gumuscu","sequence":"additional","affiliation":[{"name":"Merck &amp; Co. Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianda","family":"Yuan","sequence":"additional","affiliation":[{"name":"Merck &amp; Co. Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian L.","family":"Siu","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.12.007"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00601-1"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.20181"},{"key":"e_1_2_11_5_1","unstructured":"Coherus Biosciences Inc \u201cLOQTORZI (Toripalimab\u2010Tpzi) Injection for Intravenous Use \u201d(2025) 26."},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.21037\/anpc-21-11"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2016.0270"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1116143"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1202117"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.860700"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.05.022"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032260"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.105127"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2608"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.007"},{"issue":"6","key":"e_1_2_11_16_1","first-page":"1188","article-title":"Quantitative Analysis of Cell\u2010Free Epstein\u2010Barr Virus DNA in Plasma of Patients With Nasopharyngeal Carcinoma","volume":"59","author":"Lo Y. M.","year":"1999","journal-title":"Cancer Research"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1146898"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02712"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0587"},{"issue":"8","key":"e_1_2_11_20_1","doi-asserted-by":"crossref","first-page":"viii5","DOI":"10.1093\/annonc\/mdv514.07","article-title":"17p \u2010 Correlation Between Plasma EBV DNA and Clinical Response to Pembrolizumab in Patients With Advanced or Metastatic Nasopharyngeal Carcinoma","volume":"26","author":"Kao H. F.","year":"2015","journal-title":"Annals of Oncology"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00302-8"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.6039"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2019.0144"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.05.064"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1858"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.090696"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71496","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71496","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71496","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:26:48Z","timestamp":1786703208000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/cam4.71496"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71496","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71496"}}